These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9035091)
21. FDA flexes muscle in oversight of medical devices, technologies. Cruise C Biomed Instrum Technol; 2011; 45(2):105-8. PubMed ID: 21466325 [No Abstract] [Full Text] [Related]
23. Substantial equivalence: its uses and abuses. Miller HI Nat Biotechnol; 1999 Nov; 17(11):1042-3. PubMed ID: 10545866 [No Abstract] [Full Text] [Related]
24. Biotechnology. EPA proposal would exempt some GMOs from registry. Reardon S Science; 2011 May; 332(6030):652. PubMed ID: 21551040 [No Abstract] [Full Text] [Related]
25. Off-label drug use. Dooley AG Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258 [No Abstract] [Full Text] [Related]
26. US agbio controversies continue. Fox JL Nat Biotechnol; 1999 Jul; 17(7):628. PubMed ID: 10409343 [No Abstract] [Full Text] [Related]
27. FDA targets unapproved drugs. Young D Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170 [No Abstract] [Full Text] [Related]
28. Off-label prescribing. Legal implications. Henry V J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051 [No Abstract] [Full Text] [Related]
29. A much-anticipated FDA reform bill is signed into law: progress and compromise. Nissen SE Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992 [No Abstract] [Full Text] [Related]
31. Efficacy of labeling of foods and pharmaceuticals. Viscusi WK Annu Rev Public Health; 1994; 15():325-43. PubMed ID: 8054088 [No Abstract] [Full Text] [Related]
32. Speed and oversight: FDA Commissioner Gottlieb acts on pledges. Morrison C Nat Biotechnol; 2017 Oct; 35(10):898-899. PubMed ID: 29019996 [No Abstract] [Full Text] [Related]